Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Adial Pharmaceuticals (NASDAQ: ADIL) announced CEO Cary Claiborne will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:40 p.m. ET. The presentation will be webcast live and available for replay.
Adial management will also hold one‑on‑one meetings with approved investors during the virtual conference, held February 25–26, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – ADIL
In the Feb 17 session, ADIL declined 5.26%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.2% during that session. Argus tracked a trough of -9.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Policy tailwind | Positive | -25.8% | Congressional directive on alternative SUD endpoints seen as aiding AD04 pathway. |
| Feb 03 | Reverse stock split | Negative | -1.6% | 1-for-25 reverse split to regain Nasdaq minimum bid price compliance. |
| Jan 14 | IP protection | Positive | -1.1% | Publication of PCT patent application expected to extend AD04 IP to 2045. |
| Nov 26 | Warrant financing | Negative | +1.0% | Dilutive warrant inducement raising about $2.86M gross proceeds. |
| Nov 14 | Earnings & update | Neutral | +1.9% | Q3 2025 results with EOP2 FDA guidance and cash runway into Q2 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several positive or supportive developments (FDA feedback, IP, policy tailwinds) followed by weak or negative price reactions, while dilutive financing and structural actions have seen mixed to slightly positive responses.
Over the last six months, Adial has focused on advancing AD04 and strengthening its capital structure. An EOP2 FDA meeting and subsequent Q3 2025 update outlined an adaptive Phase 3 plan and cash runway into Q2 2026. The company raised capital via a $2.86M warrant inducement and later pursued a 1-for-25 reverse split to address Nasdaq bid-price compliance. Policy support for alternative endpoints and IP moves projecting protection to 2045 did not translate into sustained price strength, framing today’s conference appearance as part of ongoing visibility efforts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, will be presenting at the Oppenheimer 36th Annual Healthcare Life Sciences Conference which will be held virtually February 25 - 26, 2026.
Adial’s presentation is scheduled for Wednesday, February 25, 2026 at 2:40 p.m. Eastern Time. The presentation will be webcast live and available for replay at https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/UHEtM9jk8GYPk2uPyMKHVc as well as on the Company's investor relations section of the website at www.adial.com/events.
Management will also be hosting 1x1 meetings throughout the conference with approved investors.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
